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A report on the Stem Cell EuroConference, Paris, France, 9-
10 December 2004.
The stem-cell meeting held at the Institut Pasteur in December
2004 proved that the nascent field of stem-cell biology has
rapidly become one of the most exciting and active fields in
current research. Leading scientists from a range of disci-
plines relevant to stem-cell biology covered a gamut of
current topics, including the properties of human and mouse
embryonic and adult stem cells, attempts to manipulate
stem cells, and the first clinical attempts at cell-based thera-
pies. Here we describe some of the high points.
Embryonic stem cells and their potentialities
Stem cells are endowed with the ability to perpetuate them-
selves through self-renewal and to differentiate into many
specialized cell types. This remarkable dual capacity raises
many questions and holds enormous potential for regenera-
tive medicine. A crucial question is how a stem cell decides
to self-renew rather than to differentiate, and which signal-
ing pathways are at work in the two different states.
Recently, thanks to the work of several groups, including
those of Peter Andrews (University of Sheffield, UK), Austin
Smith (University of Edinburgh, UK) and our own, the mole-
cular signature underlying the ‘stemness’ state of human
embryonic stem cells (hES cells) is being defined. Andrews
reported karyotypic changes in three independent hES cell
lines involving the gain of chromosome 17q and occasionally
12p. These changes may provide a selective advantage for the
propagation of undifferentiated hES cells, and a detailed
analysis of the genes present in these chromosomal regions
might further elucidate the molecular mechanisms underly-
ing self-renewal. However, such detrimental karyotypic
changes need to be taken into account for future therapeutic
applications of hES cells. One of us (A.H.B.) reported work
in our group on the importance of the Wnt and TGFβ path-
ways in maintaining stemness. 
The fundamental challenge of work on stem cells lies in
unlocking the mechanism that directs the differentiation of
pluripotent stem cells into specific cell lineages in vitro. To
accomplish this, appropriate culture conditions must be
established so as to generate specific cell types from ES cells
and obtain homogeneous populations. Many laboratories are
working in this direction, and focusing their efforts on a spe-
cific cell type: Henrik Sembe (Lund University, Sweden)
reported progress on the differentiation of pancreatic cells
and Ron McKay (National Institute of Neurological Disor-
ders and Stroke, Bethesda, USA) on the differentiation of
dopamine neurons. Austin Smith provided an example of a
niche-independent differentiation phenomenon using a
green fluorescent protein (GFP) knock-in reporter ES cell
line in which GFP replaced the open reading frame (ORF) of
the neural-specific gene Sox1. Both mouse and human ES
cells containing the GFP reporter commit to a neural fate in
culture in vitro in the absence of serum and leukemia
inhibitor factor (LIF); 60% of the cells were GFP-positive at
4 days. Therefore, as already suggested by experiments in
amphibian embryos, no exogenous inductive stimuli (except
perhaps for autocrine fibroblast growth factor signaling)
seem to be required for the commitment of ES cells to a
neural fate. If the in vitro results with the GFP reporter are
confirmed, we have learned a lesson from embryology.
Adult stem cells and tissue repair
A substantial part of the meeting was devoted to adult stem
cells and their potential for tissue repair. Adult stem cells are
generally considered tissue-specific - only able to give rise to
progeny cells corresponding to their tissue of origin. In some
tissues, for example the liver and the pancreas, the existence
of a resident stem-cell population remains controversial.
Adult skeletal muscle can regenerate following injury and
this process seems to be mediated primarily by stem cells,
known as myogenic satellite cells, present in adult muscle
fibers. But are satellite cells the only source of skeletal
muscle regeneration? Bruno Peault (Children’s Hospital,
Pittsburgh, USA and Inserm, Villejuif, France) reported the
identification in his laboratory of alternative resident adult
stem-cell populations in skeletal muscle. His group found
that within the satellite-cell compartment in human muscle,
1% of the cells also coexpress endothelial markers; these
cells have dramatic myogenic potential in vivo. Similar
results were obtained with genuine endothelial cells sorted
from human adult muscle. Is there a stem-cell reserve in
blood-vessel walls? Perhaps the answer lies in mesoangio-
blasts, a “novel class” of mesodermal progenitor cells
described by Giulio Cossu (Stem Cell Research Institute,
Milan, Italy). These cells are physically associated with
vessels, coexpress early endothelial and myogenic markers,
and are capable of differentiating into mesodermal lineage
cells in vivo, including blood, cartilage, and skeletal and
cardiac muscle cells. In addition, wild-type or genetically
corrected mesoangioblasts delivered into the arterial blood
system can correct mouse and dog models of limb-girdle
muscular dystrophy. Taken together, these observations
suggest a lineage kinship between vascular progenitors and
progenitors of extravascular mesodermal tissue throughout
development and post-natal life. 
The existence of a resident pool of stem cells in cardiac
muscle, on the other hand, remains controversial. Ketty
Schwartz (Groupe Hospitalier Pitie-Salpetriere, Paris,
France) described the successful use of skeletal muscle satel-
lite cells as an alternative for cell-transplantation therapy for
heart failure. After successful long-term experiments in
animal models of infarcted myocardium, her group pro-
ceeded to a phase I clinical trial in a small number of
patients (ten) with severe ischemic cardiomyopathy.
Encouraging results were obtained after 10 months of
follow-up. An international phase II trial including 300
patients is in progress and the first results of this will be
available in 2006; the trial is known as MAGIC, for myoblast
autologous grafting in ischemic cardiomyopathy. Although
this is exciting news and represents the first courageous
trials carried out in patients, the approach has a fundamen-
tal limitation: skeletal myoblasts do not convert into true
cardiomyocytes and, accordingly, no electrical coupling
occurs between the host and grafted cells. Further analysis is
required if we are to identify any other, more appropriate,
sources of stem cells.
Development of a cell-based therapy for liver failure and
inherited metabolic disease has become a necessity as a
result of the limitations of liver transplantation. Several
groups are searching for an ideal source of hepatic cells for
transplantation. To try to identify a source, Markus Grompe
(University of Oregon, Eugene, USA) took a lesson from the
field of embryology, namely our knowledge about the close
developmental relationship between the pancreas and liver.
He reported that, in the fumarylacetoacetate hydrolase (FAH)
liver-disease model in the mouse, diseased livers became
repopulated with hepatocytes following intrasplenic trans-
plantation of a suspension of adult pancreatic cells. From this
he concludes that the adult pancreas contains hepatocyte
progenitor cells. Two possible scenarios can be predicted: a
differentiation event from a common hepatopancreatic stem
cell, or transdifferentiation of adult cells. 
Tissue-specific adult stem cells are not pluripotent, but
recent evidence has suggested that rare stem cells with high
developmental plasticity can be isolated from adult bone
marrow and might represent a better source for cell therapy.
The conclusion of the meeting on this was unambiguous:
both Irving Weissman (Stanford University, USA) and
Grompe reported that cell fusion rather than tissue-specific
differentiation explains how transplanted bone-marrow cells
adopt the phenotype of the host tissue. Nevertheless,
Grompe emphasized that cell fusion can be considered a rel-
evant therapeutic strategy. He described an elegant serial
transplantation approach using increasingly lineage-
restricted donor bone-marrow cell populations. This work
has shown that fusion occurs in mouse liver between host
hepatocytes and transplanted macrophages. Further insight
into the factors that govern in vivo cell fusion and the nature
of reprogramming of the macrophage nucleus to a hepato-
cyte gene-expression pattern will make this approach thera-
peutically relevant.
Cancer stem cells
Self-renewal is the hallmark of both stem cells and cancer
cells, and in his talk on leukemia stem cells, Weissman
addressed this intriguing parallel. Many pathways classically
associated with cancer also control stem-cell self-renewal.
He pointed out that stem cells continue to divide over a long
period of time and, as a consequence, they are more likely to
accumulate mutations, which may cause neoplasia. We can
thus postulate that tumors might originate from the trans-
formation of normal stem cells. Work in Weissman’s labora-
tory has established the role of a leukemia stem cell in
leukemia. If the results hold true for other tumors, the new
challenge of cancer therapy will be to identify and character-
ize the cancer stem cell in order to eliminate it. 
It is an exhilarating time for stem-cell research. The work
presented at the meeting suggested that stem-cell research
will lead to insights in a variety of fields, such as embryol-
ogy, cell-based therapy and the origin of cancer. We look
forward to seeing advances in the field, perhaps at the next
EuroConference.
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